Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Amwell CFO sells over 222,000 class A common shares » 16:35
01/22/21
01/22
16:35
01/22/21
16:35
AMWL

Amwell

$29.46 /

+0.285 (+0.98%)

In a regulatory filing,…

In a regulatory filing, American Well CFO Keith Anderson disclosed the sale of 222,054 class A common shares of the company on January 20 at a price of $26.4275 per share.

ShowHide Related Items >><<
AMWL Amwell
$29.46 /

+0.285 (+0.98%)

AMWL Amwell
$29.46 /

+0.285 (+0.98%)

01/06/21 BTIG
Amwell initiated with a Neutral at BTIG
12/17/20 Stifel
Amwell initiated with a Hold at Stifel
11/19/20 Morgan Stanley
Morgan Stanley upgraded Amwell on 'compelling' risk/reward after selloff
11/18/20 Morgan Stanley
Amwell upgraded to Overweight from Equal Weight at Morgan Stanley
AMWL Amwell
$29.46 /

+0.285 (+0.98%)

  • 15
    Jan
  • 17
    Sep
AMWL Amwell
$29.46 /

+0.285 (+0.98%)

AMWL Amwell
$29.46 /

+0.285 (+0.98%)

AMWL Amwell
$29.46 /

+0.285 (+0.98%)

Upgrade
Quidel upgraded to Outperform from Market Perform at Raymond James » 09:19
01/22/21
01/22
09:19
01/22/21
09:19
QDEL

Quidel

$218.50 /

+5.87 (+2.76%)

Raymond James analyst…

Raymond James analyst Andrew Cooper upgraded Quidel to Outperform from Market Perform with a $250 price target. Cooper believes Quidel's core business is well positioned to exit the pandemic much stronger than it entered. The analyst thinks the stock can work even amidst an eventual top-line decline on waning COVID-19 testing.

ShowHide Related Items >><<
QDEL Quidel
$218.50 /

+5.87 (+2.76%)

QDEL Quidel
$218.50 /

+5.87 (+2.76%)

01/22/21 Raymond James
Quidel upgraded to Outperform from Market Perform at Raymond James
01/08/21 Piper Sandler
Quidel selloff on Q4 revenue overdone, says Piper Sandler
11/09/20 Piper Sandler
Buy companies with COVID-19 tests on today's selloff, says Piper Sandler
10/30/20 JPMorgan
Quidel price target raised to $190 from $185 at JPMorgan
QDEL Quidel
$218.50 /

+5.87 (+2.76%)

QDEL Quidel
$218.50 /

+5.87 (+2.76%)

QDEL Quidel
$218.50 /

+5.87 (+2.76%)

Recommendations
Amarin remains undervalued under almost any scenario, says Cowen » 07:51
01/22/21
01/22
07:51
01/22/21
07:51
AMRN

Amarin

$6.31 /

+0.11 (+1.78%)

Cowen analyst Ken…

Cowen analyst Ken Cacciatore believes Amarin shares remain undervalued remain undervalued under almost any scenario and said its valuation appears too discounted. He believes the company's best path forward it to cease US promotional spending to maximize profitability and then sell the company for European value, Cacciatore maintained his Outperform rating and $10 price target on Amarin shares.

ShowHide Related Items >><<
AMRN Amarin
$6.31 /

+0.11 (+1.78%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

01/08/21 Piper Sandler
Piper sees 're-birth' for Amarin shares in 2021, keeps $19 price target
12/28/20 Cantor Fitzgerald
Vascepa showing positive year-over-year trends, says Cantor Fitzgerald
12/23/20 Goldman Sachs
Amarin price target lowered to $6 from $8 at Goldman Sachs
12/14/20 Piper Sandler
Amarin's Vascepa showed 'encouraging results' in Covid patients, says Piper
AMRN Amarin
$6.31 /

+0.11 (+1.78%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

Hot Stocks
BioCryst announces approval of ORLADEYO in Japan » 07:07
01/22/21
01/22
07:07
01/22/21
07:07
BCRX

BioCryst

$9.15 /

-0.09 (-0.97%)

BioCryst Pharmaceuticals…

BioCryst Pharmaceuticals announced that the Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing approval for oral, once-daily ORLADEYO 150 mg for prophylactic treatment of hereditary angioedema in adults and pediatric patients 12 years and older. ORLADEYO is the first and only prophylactic HAE medication approved in Japan. One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein. ORLADEYO will be commercialized in Japan by BioCryst's partner, Torii Pharmaceutical Co., Ltd. OrphanPacific, Inc. is BioCryst's representative partner in Japan and holds the marketing authorization. Torii will launch ORLADEYO in Japan following the successful completion of BioCryst's pricing negotiations with the Japanese National Health Insurance System. In December 2020, the U.S. Food & Drug Administration approved ORLADEYO in the U.S. In Europe, the European Medicines Agency validated its marketing authorization application submission for ORLADEYO and formal review of the MAA under the centralized procedure is underway. The company expects an approval decision in Europe in the second quarter of 2021. With the approval in Japan, BioCryst is eligible to receive an additional milestone payment of $15M from Torii upon receipt of a reimbursement price approval from Japan's National Health Insurance system in excess of the threshold specified in the agreement with Torii. In addition, BioCryst will receive tiered royalties ranging from 20 percent to potentially 40 percent of Japanese net sales.

ShowHide Related Items >><<
BCRX BioCryst
$9.15 /

-0.09 (-0.97%)

BCRX BioCryst
$9.15 /

-0.09 (-0.97%)

12/22/20 JMP Securities
BioCryst selloff today a buying opportunity, says JMP Securities
12/07/20 H.C. Wainwright
BioCryst price target raised to $14 from $13 at H.C. Wainwright
12/04/20 Piper Sandler
BioCryst receives on-time approval with 'clean' label, says Piper Sandler
11/23/20 Evercore ISI
BioCryst initiated with an Outperform at Evercore ISI
BCRX BioCryst
$9.15 /

-0.09 (-0.97%)

  • 28
    May
BCRX BioCryst
$9.15 /

-0.09 (-0.97%)

BCRX BioCryst
$9.15 /

-0.09 (-0.97%)

Upgrade
Quidel upgraded to Outperform from Market Perform at Raymond James » 04:47
01/22/21
01/22
04:47
01/22/21
04:47
QDEL

Quidel

$218.50 /

+5.87 (+2.76%)

Raymond James analyst…

Raymond James analyst Andrew Cooper upgraded Quidel to Outperform from Market Perform with a $250 price target.

ShowHide Related Items >><<
QDEL Quidel
$218.50 /

+5.87 (+2.76%)

QDEL Quidel
$218.50 /

+5.87 (+2.76%)

01/08/21 Piper Sandler
Quidel selloff on Q4 revenue overdone, says Piper Sandler
11/09/20 Piper Sandler
Buy companies with COVID-19 tests on today's selloff, says Piper Sandler
10/30/20 JPMorgan
Quidel price target raised to $190 from $185 at JPMorgan
10/05/20 William Blair
Quidel emergency use news may be getting overlooked, says William Blair
QDEL Quidel
$218.50 /

+5.87 (+2.76%)

QDEL Quidel
$218.50 /

+5.87 (+2.76%)

QDEL Quidel
$218.50 /

+5.87 (+2.76%)

Thursday
On The Fly
Fly Intel: After-Hours Movers » 18:35
01/21/21
01/21
18:35
01/21/21
18:35
SIVB

SVB Financial

$455.02 /

-7.49 (-1.62%)

, WAL

Western Alliance

$69.40 /

-1.92 (-2.69%)

, INDB

Independent Bank

$78.68 /

-1.39 (-1.74%)

, OZK

Bank OZK

$34.03 /

-0.59 (-1.70%)

, FLDM

Fluidigm

$6.17 /

+0.31 (+5.29%)

, MNOV

MediciNova

$5.78 /

+0.09 (+1.58%)

, SWIR

Sierra Wireless

$18.41 /

+0.02 (+0.11%)

, ALDX

Aldeyra

$11.77 /

-0.48 (-3.92%)

, AMRN

Amarin

$6.31 /

+0.11 (+1.78%)

, IBM

IBM

$131.80 /

+1.72 (+1.32%)

, STX

Seagate

$63.00 /

+1.57 (+2.56%)

, PPG

PPG

$143.94 /

-0.635 (-0.44%)

, ISRG

Intuitive Surgical

$799.43 /

-0.18 (-0.02%)

, CSX

CSX

$91.61 /

-1.6101 (-1.73%)

, PGEN

Precigen

$9.18 /

-0.22 (-2.34%)

, ACB

Aurora Cannabis

$11.17 /

-0.39 (-3.37%)

, F

Ford

$11.53 /

+0.665 (+6.12%)

Check out this evening's…

ShowHide Related Items >><<
SWIR Sierra Wireless
$18.41 /

+0.02 (+0.11%)

STX Seagate
$63.00 /

+1.57 (+2.56%)

SIVB SVB Financial
$455.02 /

-7.49 (-1.62%)

PPG PPG
$143.94 /

-0.635 (-0.44%)

PGEN Precigen
$9.18 /

-0.22 (-2.34%)

OZK Bank OZK
$34.03 /

-0.59 (-1.70%)

MNOV MediciNova
$5.78 /

+0.09 (+1.58%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

IBM IBM
$131.80 /

+1.72 (+1.32%)

FLDM Fluidigm
$6.17 /

+0.31 (+5.29%)

F Ford
$11.53 /

+0.665 (+6.12%)

CSX CSX
$91.61 /

-1.6101 (-1.73%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

ALDX Aldeyra
$11.77 /

-0.48 (-3.92%)

ACB Aurora Cannabis
$11.17 /

-0.39 (-3.37%)

SIVB SVB Financial
$455.02 /

-7.49 (-1.62%)

01/08/21 Oppenheimer
Oppenheimer calls SVB Financial acquisition of Boston Private a 'good move'
01/05/21 DA Davidson
SVB Financial price target raised to $400 from $365 at DA Davidson
01/05/21 Raymond James
SVB Financial price target raised to $440 from $325 at Raymond James
01/05/21 RBC Capital
SVB Financial price target raised to $437 from $320 at RBC Capital
WAL Western Alliance
$69.40 /

-1.92 (-2.69%)

01/08/21 UBS
Western Alliance upgraded to Buy from Neutral at UBS
01/04/21 Stephens
Brinker, LiveRamp and Vonage among 2021 best ideas at Stephens
12/15/20 Truist
Truist raises price targets on select regional banks
11/04/20 Stephens
Western Alliance resumed with an Overweight at Stephens
INDB Independent Bank
$78.68 /

-1.39 (-1.74%)

12/17/20 Seaport Global
Seaport Global rolls out coverage of Regional and Community Banks with 4 Buys
12/17/20 Seaport Global
Independent Bank initiated with a Neutral at Seaport Global
10/26/20 Compass Point
Independent Bank upgraded to Buy from Neutral at Compass Point
06/24/20 Piper Sandler
Independent Bank downgraded to Neutral from Overweight at Piper Sandler
OZK Bank OZK
$34.03 /

-0.59 (-1.70%)

06/17/20 Raymond James
Bank OZK upgraded to Outperform from Market Perform at Raymond James
06/17/20 Citi
Bank OZK downgraded to Neutral from Buy at Citi
06/17/20 Raymond James
Bank OZK upgraded to Outperform from Market Perform at Raymond James
04/28/20 Truist
Bank OZK price target raised to $22 from $19 at SunTrust
FLDM Fluidigm
$6.17 /

+0.31 (+5.29%)

12/17/20 BTIG
Illumina upgraded to Buy from Neutral at BTIG
11/09/20 Piper Sandler
Buy companies with COVID-19 tests on today's selloff, says Piper Sandler
10/19/20 Piper Sandler
Fluidigm test pact in Texas 'another validation,' says Piper Sandler
09/29/20 Piper Sandler
Piper Sandler would be buyers of Fluidigm given recent pullback
MNOV MediciNova
$5.78 /

+0.09 (+1.58%)

SWIR Sierra Wireless
$18.41 /

+0.02 (+0.11%)

01/14/21
Fly Intel: Top five analyst initiations
01/14/21 B. Riley Securities
Sierra Wireless initiated with a Buy at B. Riley Securities
11/25/20 Colliers
Sierra Wireless initiated with a Buy at Colliers
02/14/20 Roth Capital
Roth Capital sees upside in Sierra Wireless after 2020 transition year
ALDX Aldeyra
$11.77 /

-0.48 (-3.92%)

01/08/21 Jefferies
Aldeyra could double if topline of TRANQUILITY study positive, says Jefferies
01/08/21 Citi
Aldeyra shares have 'plenty of upside' despite 26% rally, says Citi
01/07/21 Alliance Global Partners
Aldeyra in an 'enviable position' after Phase 3 Tranquility data, says AGP
12/16/20 Berenberg
Berenberg starts Aldeyra with Buy, sees near-term catalysts
AMRN Amarin
$6.31 /

+0.11 (+1.78%)

01/08/21 Piper Sandler
Piper sees 're-birth' for Amarin shares in 2021, keeps $19 price target
12/28/20 Cantor Fitzgerald
Vascepa showing positive year-over-year trends, says Cantor Fitzgerald
12/23/20 Goldman Sachs
Amarin price target lowered to $6 from $8 at Goldman Sachs
12/14/20 Piper Sandler
Amarin's Vascepa showed 'encouraging results' in Covid patients, says Piper
IBM IBM
$131.80 /

+1.72 (+1.32%)

10/20/20 Morgan Stanley
Morgan Stanley continues to view IBM as 'a 2022 stock'
10/20/20 Citi
IBM is 'getting even more complex,' says Citi
10/20/20 BMO Capital
IBM price target lowered to $138 from $140 at BMO Capital
10/09/20 Morgan Stanley
IBM price target raised to $140 from $128 at Morgan Stanley
STX Seagate
$63.00 /

+1.57 (+2.56%)

01/21/21 Barclays
Seagate price target raised to $60 from $41 at Barclays
01/20/21 Wedbush
Seagate price target raised to $56 from $47 at Wedbush
01/19/21 Northland
Seagate price target raised to $72 from $65 at Northland
01/19/21 Loop Capital
Seagate price target raised to $70 from $60 at Loop Capital
PPG PPG
$143.94 /

-0.635 (-0.44%)

01/20/21 Citi
Citi adds PPG to US Focus List, removes FMC
01/14/21 Berenberg
PPG upgraded to Buy with $165 price target at Berenberg
01/14/21 Berenberg
PPG upgraded to Buy from Hold at Berenberg
12/01/20 Deutsche Bank
PPG price target raised to $165 from $155 at Deutsche Bank
ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

12/15/20 Morgan Stanley
Intuitive Surgical downgraded to Equal Weight on valuation at Morgan Stanley
12/15/20 Morgan Stanley
Intuitive Surgical downgraded to Equal Weight from Overweight at Morgan Stanley
11/24/20 Raymond James
Intuitive Surgical not surprised by J&J robot features, says Raymond James
10/16/20 JPMorgan
Intuitive Surgical price target raised to $785 from $765 at JPMorgan
CSX CSX
$91.61 /

-1.6101 (-1.73%)

01/20/21 Susquehanna
Railroad recovery expected to continue in 2021, says Susquehanna
01/11/21 Citi
CSX price target raised to $105 from $87 at Citi
12/10/20 Morgan Stanley
Morgan Stanley downgrades CSX to Underweight with bar raised too high
12/10/20 Morgan Stanley
CSX downgraded to Underweight from Equal Weight at Morgan Stanley
PGEN Precigen
$9.18 /

-0.22 (-2.34%)

12/16/20 H.C. Wainwright
Precigen price target raised to $10 from $8 at H.C. Wainwright
05/08/20
Fly Intel: Top analyst initiations
05/08/20 H.C. Wainwright
Precigen initiated with a Buy at H.C. Wainwright
ACB Aurora Cannabis
$11.17 /

-0.39 (-3.37%)

01/06/21 BMO Capital
Federal cannabis reform in U.S. likely to take time, says BMO Capital
12/17/20 BMO Capital
Aurora Cannabis downgraded to Underperform from Market Perform at BMO Capital
12/04/20 Alliance Global Partners
Alliance Global sees low odds of MORE Act passing this congressional session
12/02/20 Alliance Global Partners
Alliance Global Partners sees UN cannabis reclassification helping legalization
F Ford
$11.53 /

+0.665 (+6.12%)

01/20/21 Deutsche Bank
Ford price target raised to $11 from $9 at Deutsche Bank
01/20/21 Deutsche Bank
Ford named 'Catalyst Call: Buy Idea' at Deutsche Bank
01/05/21 Benchmark
GM, Roku, Marcus among Benchmark's Best Ideas for first half of 2021
12/23/20 Morgan Stanley
Apple's potential EV entry represents 'new Tesla bear case,' says Morgan Stanley
WAL Western Alliance
$69.40 /

-1.92 (-2.69%)

SWIR Sierra Wireless
$18.41 /

+0.02 (+0.11%)

STX Seagate
$63.00 /

+1.57 (+2.56%)

SIVB SVB Financial
$455.02 /

-7.49 (-1.62%)

PPG PPG
$143.94 /

-0.635 (-0.44%)

PGEN Precigen
$9.18 /

-0.22 (-2.34%)

OZK Bank OZK
$34.03 /

-0.59 (-1.70%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

INDB Independent Bank
$78.68 /

-1.39 (-1.74%)

IBM IBM
$131.80 /

+1.72 (+1.32%)

FLDM Fluidigm
$6.17 /

+0.31 (+5.29%)

F Ford
$11.53 /

+0.665 (+6.12%)

CSX CSX
$91.61 /

-1.6101 (-1.73%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

ALDX Aldeyra
$11.77 /

-0.48 (-3.92%)

ACB Aurora Cannabis
$11.17 /

-0.39 (-3.37%)

  • 22
    Jan
  • 22
    Jan
  • 14
    Jan
  • 11
    Nov
IBM IBM
$131.80 /

+1.72 (+1.32%)

FLDM Fluidigm
$6.17 /

+0.31 (+5.29%)

F Ford
$11.53 /

+0.665 (+6.12%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

ACB Aurora Cannabis
$11.17 /

-0.39 (-3.37%)

STX Seagate
$63.00 /

+1.57 (+2.56%)

SIVB SVB Financial
$455.02 /

-7.49 (-1.62%)

PPG PPG
$143.94 /

-0.635 (-0.44%)

MNOV MediciNova
$5.78 /

+0.09 (+1.58%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

IBM IBM
$131.80 /

+1.72 (+1.32%)

FLDM Fluidigm
$6.17 /

+0.31 (+5.29%)

F Ford
$11.53 /

+0.665 (+6.12%)

CSX CSX
$91.61 /

-1.6101 (-1.73%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

ACB Aurora Cannabis
$11.17 /

-0.39 (-3.37%)

STX Seagate
$63.00 /

+1.57 (+2.56%)

PPG PPG
$143.94 /

-0.635 (-0.44%)

PGEN Precigen
$9.18 /

-0.22 (-2.34%)

MNOV MediciNova
$5.78 /

+0.09 (+1.58%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

IBM IBM
$131.80 /

+1.72 (+1.32%)

FLDM Fluidigm
$6.17 /

+0.31 (+5.29%)

F Ford
$11.53 /

+0.665 (+6.12%)

CSX CSX
$91.61 /

-1.6101 (-1.73%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

ACB Aurora Cannabis
$11.17 /

-0.39 (-3.37%)

Hot Stocks
Amarin announces CSC included icosapent ethyl in CD prevention guidelines » 18:27
01/21/21
01/21
18:27
01/21/21
18:27
AMRN

Amarin

$6.31 /

+0.11 (+1.78%)

The company states:…

The company states: "Amarin announced that the Chinese Society of Cardiology, or CSC, has included icosapent ethyl in its updated Guidelines for Primary Prevention of Cardiovascular Diseases for 2021 as published in the Chinese Journal of Cardiovascular Diseases. The guideline authors include "icosapent ethyl grams twice a day as a treatment consideration to further lower atherosclerotic cardiovascular disease (ASCVD) in the appropriate patient population. In November 2020, Amarin shared positive, statistically significant top-line results from a Phase 3 clinical trial of VASCEPA conducted in China by Amarin's partner, Edding. The study, which investigated VASCEPA as a treatment for patients with very high triglycerides (greater than or equal to500 mg/dL), met its primary efficacy endpoint and demonstrated a safety profile similar to placebo. This pivotal study mirrored Amarin's MARINE study in patients from the United States and other countries and showed consistency across the Chinese and non-Chinese study populations. These findings will provide support as Edding progresses towards and through the next steps of regulatory submission and review of VASCEPA for potential approval in Mainland China. The CSC recommendation is classified as a Category IIa recommendation denoting that icosapent ethyl is useful and effective and should be considered for treatment of at-risk patients. The classification is an Evidence Level B recommendation which reflects that the evidence comes from a single randomized trial or multiple large non-randomized studies. CSC cited that its recommendations are supported by the results of the REDUCE-IT cardiovascular outcomes study. The CSC does not provide endorsements of any brand name commercial product. Accordingly, CSC Guidelines for Primary Prevention of Cardiovascular Diseases reference icosapent ethyl. The CSC guideline does not reference VASCEPA, the brand name of icosapent ethyl in the United States, and such guideline should not be construed as an endorsement or approval by the CSC of VASCEPA."

ShowHide Related Items >><<
AMRN Amarin
$6.31 /

+0.11 (+1.78%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

01/08/21 Piper Sandler
Piper sees 're-birth' for Amarin shares in 2021, keeps $19 price target
12/28/20 Cantor Fitzgerald
Vascepa showing positive year-over-year trends, says Cantor Fitzgerald
12/23/20 Goldman Sachs
Amarin price target lowered to $6 from $8 at Goldman Sachs
12/14/20 Piper Sandler
Amarin's Vascepa showed 'encouraging results' in Covid patients, says Piper
AMRN Amarin
$6.31 /

+0.11 (+1.78%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

Wednesday
Hot Stocks
Illumina wins patent infringement suit against BGI in U.K. » 16:06
01/20/21
01/20
16:06
01/20/21
16:06
ILMN

Illumina

$402.10 /

+11.62 (+2.98%)

The company states:…

The company states: "Illumina announced that the High Court of Justice, Chancery Division, Patents Court, issued a judgment in its favor in the patent infringement suit filed against the BGI Companies, MGI Tech Co. Ltd; Latvia MGI SIA; MGI International Sales Co., Ltd; and BGI Complete Genomics Hong Kong Co., Ltd. Courts in the US, Germany, Spain, Finland and Sweden have issued injunctions against BGI. The Court had previously issued a preliminary injunction against BGI's UK-based sequencing laboratory and restricted BGI's ability to supply the infringing sequencing systems in the UK. Illumina intends to seek a permanent injunction fully prohibiting the supply or sale of BGI's StandardMPS and CoolMPS systems in the UK until the relevant patents expire. Additional lawsuits are pending in Hong Kong S.A.R., France, Belgium, Denmark, Switzerland, Turkey and Italy."

ShowHide Related Items >><<
ILMN Illumina
$402.10 /

+11.62 (+2.98%)

ILMN Illumina
$402.10 /

+11.62 (+2.98%)

12/22/20
Fly Intel: Top five analyst upgrades
12/22/20 OTR Global
Illumina upgraded to Positive from Mixed at OTR Global
12/22/20 Piper Sandler
Illumina upgraded to Overweight from Neutral at Piper Sandler
12/17/20 BTIG
Illumina upgraded to Buy from Neutral at BTIG
ILMN Illumina
$402.10 /

+11.62 (+2.98%)

ILMN Illumina
$402.10 /

+11.62 (+2.98%)

ILMN Illumina
$402.10 /

+11.62 (+2.98%)

ILMN Illumina
$402.10 /

+11.62 (+2.98%)

Recommendations
1Life Healthcare jumps after William Blair sees vaccine rollout benefits » 09:45
01/20/21
01/20
09:45
01/20/21
09:45
ONEM

1Life Healthcare

$50.37 /

+2.68 (+5.62%)

William Blair analyst…

William Blair analyst Ryan Daniels sees 1Life Healthcare as a potential derivative beneficiary from the administration of Covid-19 vaccines. The company's support for vaccines in New York, Seattle and the San Francisco area, coupled with its plans to provide complimentary services to qualifying patients, could increase sales from vaccinations and "serve as a bit of a Trojan-horse marketing campaign to acquire new members," Daniels told investors earlier in a research note. The analyst keeps an Outperform rating on the shares. 1Life Healthcare in early trading is 9%, or $4.51, to $52.22.

ShowHide Related Items >><<
ONEM 1Life Healthcare
$50.37 /

+2.68 (+5.62%)

ONEM 1Life Healthcare
$50.37 /

+2.68 (+5.62%)

01/19/21 JPMorgan
Teladoc remains top 2021 healthcare technology pick at JPMorgan
01/08/21 Piper Sandler
1Life Healthcare price target raised to $51 from $44 at Piper Sandler
01/07/21 Canaccord
1Life Healthcare price target raised to $50 from $46 at Canaccord
01/06/21 BTIG
1Life Healthcare initiated with a Neutral at BTIG
ONEM 1Life Healthcare
$50.37 /

+2.68 (+5.62%)

  • 23
    Nov
  • 25
    Jun
  • 31
    Jan
ONEM 1Life Healthcare
$50.37 /

+2.68 (+5.62%)

ONEM 1Life Healthcare
$50.37 /

+2.68 (+5.62%)

Downgrade
ShockWave Medical downgraded to Neutral from Overweight at Piper Sandler » 05:00
01/20/21
01/20
05:00
01/20/21
05:00
SWAV

ShockWave Medical

$142.06 /

+5 (+3.65%)

Piper Sandler analyst…

Piper Sandler analyst Adam Maeder downgraded ShockWave Medical to Neutral from Overweight with a price target of $132, up from $96. The analyst steps to the sidelines "for the time being due to valuation." Additionally, he believes the resurgence of COVID-19 cases and "fairly high" buy-side expectations make for a "less-than-optimal" setup heading into the Q4 results. Maeder thinks the stock already reflects some upside to numbers and is unsure how much more multiple expansion will materialize over the next 12 months.

ShowHide Related Items >><<
SWAV ShockWave Medical
$142.06 /

+5 (+3.65%)

SWAV ShockWave Medical
$142.06 /

+5 (+3.65%)

01/13/21 Piper Sandler
MCIT finalized rule 'important win' for medical technology, says Piper Sandler
01/12/21 Wells Fargo
ShockWave Medical price target raised to $134 from $95 at Wells Fargo
12/03/20 Piper Sandler
Piper boosts ShockWave Medical target to $96, likes setup into 2021
12/02/20 Oppenheimer
Oppenheimer stays at Perform on ShockWave, highlights paper on IVL-induced VFib
SWAV ShockWave Medical
$142.06 /

+5 (+3.65%)

  • 17
    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.